Candriam S.C.A. Crinetics Pharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
243Shares Held
80MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$244 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$242 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$228 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$192 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$173 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.09B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...